Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Mayo researchers to announce new findings about promising early-stage breast cancer treatment

17.05.2005


NCCTG investigations yield additional significant data



A study led by a Mayo Clinic medical oncologist and conducted by the North Central Cancer Treatment Group (NCCTG) provides important new data about the effectiveness and safety of a breast cancer treatment combining chemotherapy and a drug called trastuzumab (Herceptin).

According to Mayo Clinic medical oncologist and NCCTG study chair Edith Perez, M.D., these results could change the standard of care for thousands of women with breast cancer. "Women with HER-2 positive breast cancer had a high risk of the cancer returning and of dying from breast cancer. This intervention -- chemotherapy plus trastuzumab -- essentially changes the natural history of the disease," says Dr. Perez.


The National Cancer Institute (NCI) sponsored two large, multicenter clinical trials studying more than 3,300 women with breast cancer between February 2000 and April 2005. These two Phase III trials were conducted by NCCTG and the National Surgical Adjuvant Breast and Bowel Project (NSABP), in collaboration with other research groups throughout the United States.

Dr. Perez, from Mayo Clinic in Jacksonville, Fla., will report results from the NCCTG trial (N9831) on Monday, May 16, at the 2005 American Society of Clinical Oncology (ASCO) Annual Meeting in Orlando, Fla.

The NCCTG trial is the only study that will offer new data comparing whether trastuzumab is more effective in preventing recurrence when it’s given during (concurrently) or after (sequentially) chemotherapy. These findings will be important tools to help oncologists determine how to optimize trastuzumab’s protective effect in the course of treating patients with HER-2 positive breast cancer.

"Our preliminary data show that sequential treatment is good, but trastuzumab given concurrently with chemotherapy yielded important trends for better results. Although longer follow-up is needed, this difference led to the recommendation that study participants who are currently receiving chemotherapy should receive trastuzumab at the same time as the paclitaxel, instead of waiting," says Dr. Perez.

Lee Aase | EurekAlert!
Further information:
http://www.mayo.edu
http://www.mayoclinic.com

More articles from Studies and Analyses:

nachricht Real-time feedback helps save energy and water
08.02.2017 | Otto-Friedrich-Universität Bamberg

nachricht The Great Unknown: Risk-Taking Behavior in Adolescents
19.01.2017 | Max-Planck-Institut für Bildungsforschung

All articles from Studies and Analyses >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Breakthrough with a chain of gold atoms

In the field of nanoscience, an international team of physicists with participants from Konstanz has achieved a breakthrough in understanding heat transport

In the field of nanoscience, an international team of physicists with participants from Konstanz has achieved a breakthrough in understanding heat transport

Im Focus: DNA repair: a new letter in the cell alphabet

Results reveal how discoveries may be hidden in scientific “blind spots”

Cells need to repair damaged DNA in our genes to prevent the development of cancer and other diseases. Our cells therefore activate and send “repair-proteins”...

Im Focus: Dresdner scientists print tomorrow’s world

The Fraunhofer IWS Dresden and Technische Universität Dresden inaugurated their jointly operated Center for Additive Manufacturing Dresden (AMCD) with a festive ceremony on February 7, 2017. Scientists from various disciplines perform research on materials, additive manufacturing processes and innovative technologies, which build up components in a layer by layer process. This technology opens up new horizons for component design and combinations of functions. For example during fabrication, electrical conductors and sensors are already able to be additively manufactured into components. They provide information about stress conditions of a product during operation.

The 3D-printing technology, or additive manufacturing as it is often called, has long made the step out of scientific research laboratories into industrial...

Im Focus: Mimicking nature's cellular architectures via 3-D printing

Research offers new level of control over the structure of 3-D printed materials

Nature does amazing things with limited design materials. Grass, for example, can support its own weight, resist strong wind loads, and recover after being...

Im Focus: Three Magnetic States for Each Hole

Nanometer-scale magnetic perforated grids could create new possibilities for computing. Together with international colleagues, scientists from the Helmholtz Zentrum Dresden-Rossendorf (HZDR) have shown how a cobalt grid can be reliably programmed at room temperature. In addition they discovered that for every hole ("antidot") three magnetic states can be configured. The results have been published in the journal "Scientific Reports".

Physicist Dr. Rantej Bali from the HZDR, together with scientists from Singapore and Australia, designed a special grid structure in a thin layer of cobalt in...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

Booth and panel discussion – The Lindau Nobel Laureate Meetings at the AAAS 2017 Annual Meeting

13.02.2017 | Event News

Complex Loading versus Hidden Reserves

10.02.2017 | Event News

International Conference on Crystal Growth in Freiburg

09.02.2017 | Event News

 
Latest News

Switched-on DNA

20.02.2017 | Materials Sciences

Second cause of hidden hearing loss identified

20.02.2017 | Health and Medicine

Prospect for more effective treatment of nerve pain

20.02.2017 | Health and Medicine

VideoLinks
B2B-VideoLinks
More VideoLinks >>>